|GRANTWAY
EN

Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clin…

National Institutes of Health

Share
Favorite
Feedback
Summary
-
14 February 2025
-
-
-
For profit
United States of America
Education, Skills Building and Training Health, Justice and Social Welfare
Research, Development and Innovation Social Sciences
Overview

This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing research projects, directed towards commercialization, for the development of novel, evidence-based, FDA-regulated medical products addressing the needs of patients suffering from opioid use disorders (OUD) and stimulant use disorders (StUD). Applications received under this FOA may fall within two scientific areas, namely: (1) pharmacotherapeutics (small molecules and biologics; and (2) medical therapeutic and diagnostic devices, including software as a medical device. This FOA strives to contribute to the effort against national opioid and psychostimulant emergency and offer new medical products for individuals, families, and communities affected by this devastating crisis.

Eligibility

Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.

Learn more or apply
All information about this funding has been collected from and belongs to the funding organization
20 April 2023